Today: 9 June 2026
South Korea delays first STO exchange licences as Lucentblock-Nextrade fight heats up
14 January 2026
2 mins read

South Korea delays first STO exchange licences as Lucentblock-Nextrade fight heats up

Seoul, January 14, 2026, 18:32 (KST)

  • Reports said South Korea’s FSC held off on deciding about preliminary licenses for an STO-focused OTC marketplace at its Jan. 14 meeting.
  • Startup Lucentblock claims it was unfairly sidelined and accuses Nextrade of misusing information shared under an NDA; Nextrade denies any misconduct.
  • These licences will determine the operators of the country’s first regulated trading platforms for tokenised securities.

South Korea’s financial regulator delayed its decision on preliminary licences for new over-the-counter marketplaces for tokenised securities on Wednesday. The move came amid public disagreements over the approval process, according to reports and industry sources.

South Korea has taken a crucial step toward integrating security token offerings (STOs)—digital securities tracked on blockchain—into its regulated financial system, following years of pilot programs. Proponents argue this will open the door for small investors to buy fractions of assets like real estate, music copyrights, and art, instead of needing to purchase entire properties or full rights.

The Financial Services Commission (FSC) was set to pick up to two preliminary winners from three contenders: consortia headed by Korea Exchange-Koscom (KDX), alternative trading platform operator Nextrade (NXT), and a group led by Lucentblock. The decision’s delay leaves the ranking unsettled and ramps up pressure on Lucentblock, which has cautioned it might have to shut down if excluded.

Lucentblock, operating a real estate fractional investment platform within the regulator’s sandbox programme, claims first movers are being sidelined now that formal licenses are rolling out. CEO Huh Se-young said, “I felt abandoned after serving as a government test case.”

The company claims Nextrade misused information received under a non-disclosure agreement, alleging it was pitched as a potential investor or partner before swiftly filing for the same business line. Lucentblock says the shared data covered internal financial and technical specifics.

Nextrade has dismissed the allegations, calling the complaint an effort to disrupt the licensing process. “We have disclosed the full list and volume of the materials received,” the company said, stressing that the final approval lies with financial authorities.

The dispute has expanded into a broader debate over whether the FSC is prioritizing innovation or institutional clout. According to local media, the regulator’s official criteria emphasize licensing under the Capital Markets Act, giving additional points for consortium composition and launch preparedness. An FSC spokesperson added, “No conclusion has been reached yet.” Asiae

NXT’s team insists it isn’t an exclusive circle dominated by big finance, highlighting involvement from fractional investment firms like Musicow, Sejong DX, Stock Keeper, and Together Art, alongside a wider mix of securities and finance companies. Lucentblock, on the other hand, presents itself as a single-startup consortium and argues this shouldn’t be viewed as a disadvantage.

But the longer the standoff drags on, the greater the risk to the market’s rollout. Musicow flagged this week that “If this controversy causes the market’s opening to be postponed, the damage will not be limited to one company,” casting the delay as a threat to the entire fractional investment sector. KoreaTechDesk

Legal experts warn the dispute threatens South Korea’s regulatory sandbox promise — where tested concepts can earn permanent licenses — instead of serving as free market research for better-funded players. Attorney Hee-chul Ahn of DLG Law Firm described the sandbox as “a national commitment to commercialization for innovative companies.” venturesquare.net

Stock Market Today

  • J.M. Smucker Shares Rise After Earnings Beat Despite Sales Warning
    June 9, 2026, 10:05 AM EDT. J.M. Smucker shares rose 3.16% in pre-market trading after the company reported a 20% rise in adjusted earnings per share to $2.77, beating Wall Street estimates. The packaged-food firm grew net sales by 6% to $2.27 billion in Q4 but issued a cautionary note, forecasting a 3-4% decline in annual sales for fiscal 2027, below analysts' expectations of 1% growth. CEO Mark Smucker highlighted a focus on organic volume growth and profit improvement amid shifts in industry pricing strategies. Coffee sales drove quarterly results with a 12% retail sales increase but volume declines. The company flagged risks including consumer shifts to store brands, weight-loss drug impacts, and tariff fluctuations. Smucker's outlook balances lower sales with improved profitability.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
BHP stock ends higher as China’s iron ore surge meets merger talk — what’s next for ASX:BHP
Previous Story

BHP stock ends higher as China’s iron ore surge meets merger talk — what’s next for ASX:BHP

Nvidia stock braces for a China shock as customs blocks H200 AI chips despite U.S. export nod
Next Story

Nvidia stock braces for a China shock as customs blocks H200 AI chips despite U.S. export nod

Go toTop